Brand Name(s): Gemzar
CAS nº: 95058-81-4
(gem SIGH tah bean)
About Gemcitabine
This site is dedicated exclusively to gemcitabine.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about gemcitabine on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total gemcitabine experience!
Why is this medication prescribed?
Gemcitabine is a cancer (antineoplastic) medication. It acts by interfering with the growth of cancer cells and slows their growth and spread in the body.
This medicine is used to treat pancreatic cancer, particularly when it has metastasized, or spread to other parts of the body (Stage IVB). In combination with the drug cisplatin, gemcitabine is the first-line treatment for inoperable, metastasized non-small cell lung cancer.
Sometimes it is also used to treat cancers of the bladder or breast, or epithelial ovarian cancer.
Gemcitabine's brand name is Gemzar®.
Latest News
SciClone Initiates Phase 2 Trial of RP101 in Late-Stage Pancreatic Cancer Patients
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the first patient has been dosed...
[more]Gemcitabine/Bevacizumab Plus Radiation Appear Active in Patients With Pancreatic Cancer: Presented at ASCO-GI
Doctors said that the combination of gemcitabine and bevacizumab along with radiation in the...
[more]Conformal Radiation With Gemcitabine and Erlotinib Feasible in Unresected Pancreatic Cancer Patients: Presented at ASCO-GI
Patients with pancreatic cancer appear to tolerate the standard chemotherapy agent gemcitabine in...
[more]Shilpa cancer drugs get Korean nod
Raichur, Karnataka-based Shilpa Medicare has got South Korean Food and Drug Administration (KFDA)...
[more]Gemzar® plus Second Chemotherapy Agent Provides Small Survival Benefits in Advanced Pancreatic Cancer
According to results recently published in the journal Drugs and Aging, the combination of Gemzar®...
[more]